Objectives:
Primary
- To evaluate the equivalence of the time on active surveillance before an active treatment
between group Epstein + and the expanded active surveillance group (Epstein -)
Secondary
- To evaluate the role of diffusion-weighted MRI (DW-MRI) in the initial diagnosis and
the follow-up of patients under active surveillance
- To evaluate the role of BCAR-1 to predict the clinical outcome of localized prostate
cancer
- To evaluate patients quality of life
- To evaluate the proportion of patients who discontinued active surveillance
- To evaluate the mortality at 10, 15 and 20 years from the inclusion in the study
- To evaluate the time to metastatic disease
- To evaluate the time to radical treatment
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of patients on active surveillance in group Epstein + and Epstein -
6 years
Yes
Patrice Jichlinski, MD
Principal Investigator
Centre Hospitalier Universitaire Vaudois
Switzerland: Ethikkommission
CHUV Active surveillance
NCT01795365
December 2012
October 2017
Name | Location |
---|